STEVEN ROGERS: Open Payments
NPI 1386993509 · ROSEVILLE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,066 in 56 payments from 17 companies in 2025. Trend: 2023 $632 · 2024 $881 · 2025 $1,066
Food & beverage: $1,066
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $189 |
| ABBVIE INC. | 11 | $166 |
| GlaxoSmithKline, LLC. | 5 | $88 |
| Lilly USA, LLC | 3 | $68 |
| Aimmune Therapeutics, Inc. | 3 | $55 |
| SANOFI-AVENTIS U.S. LLC | 2 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $30 |
Products named: CAPLYTA, VRAYLAR, TRELEGY ELLIPTA, Wegovy, ZENPEP, Ozempic, MOUNJARO, TZIELD.
Industry payments across MI — which companies pay providers there.
